Pregnane X Receptor Activation Induces Ferroptosis Resistance Through Upregulation of FSP1
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.70016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Yingying Shang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. Hauptthemen laut MEDLINE: Ferroptosis, Pregnane X Receptor, S100 Calcium-Binding Protein A4. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: This study was supported by the National Natural Science Foundation of China (81972564) and the Talents Cultivation Project of the Third Military Medical Unive….
Abstract (Originalsprache)
Ferroptosis, an iron‐dependent form of programmed cell death, is emerging as a novel approach to tackling cancer. Cancer cells require large amounts of iron for their rapid growth, making them intrinsically vulnerable to ferroptosis. However, cancer cells have developed several important antioxidant pathways to counteract ferroptosis. One of these key pathways is the FSP1/CoQH2 pathway. In this study, we reveal a new regulatory mechanism of FSP1 involving the Pregnane X Receptor (PXR). Activation of PXR by rifaximin and rifampicin suppresses ferroptosis in a variety of cancer cells from different origins. The protective effect of rifaximin and rifampicin is lost in PXR knockout cells or in the presence of PXR inhibitor, validating the role of PXR in mediating the effects of these drugs. Additionally, rifaximin and rifampicin decrease lipid peroxidation and ferrous iron accumulation during ferroptosis induction, effects that are reversed in PXR knockout cells. Mechanistically, rifaximin and rifampicin induce the expression of FSP1 in a PXR‐dependent manner, as they fail to induce FSP1 in PXR knockout cells. Furthermore, the ferroptosis protection effect of rifaximin and rifampicin is significantly compromised in FSP1 knockout cells or in the presence of the FSP1 inhibitor iFSP1. Importantly, we demonstrated that the PXR inhibitor pimecrolimus showed synergy with ferroptosis inducer sulfasalazine to repress tumor growth in vivo. Together, these findings provide evidence supporting an anti‐ferroptosis role of PXR through the upregulation of FSP1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
- Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
- NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing, China.
- Department of Hematology of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Zunyi Medical University, Zunyi, China.
- Division of Liver Surgery and NHC Key Lab of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Förderung
- This study was supported by the National Natural Science Foundation of China (81972564) and the Talents Cultivation Project of the Third Military Medical Unive…
Zitieren
APA
Shang, Y., Yao, Q., Tan, Y., Bian, R., Ma, Y., Zhou, Y., Mu, R., Xu, N., Shi, Y., Lu, N., Liu, L., Chen, J., Xu, S., & Li, H. (2025). Pregnane X Receptor Activation Induces Ferroptosis Resistance Through Upregulation of FSP1. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70016
Vancouver
Shang Y, Yao Q, Tan Y, Bian R, Ma Y, Zhou Y, et al. Pregnane X Receptor Activation Induces Ferroptosis Resistance Through Upregulation of FSP1. Molecular Carcinogenesis. 2025. doi:10.1002/mc.70016
BibTeX
@article{Shang2025,
author = {Shang, Yingying and Yao, Qi and Tan, Ya and Bian, Ruipeng and Ma, Yanni and Zhou, Yuanze and Mu, Rong and Xu, Nahua and Shi, Yanyun and Lu, Nan and Liu, Lin and Chen, Jieping and Xu, Shuangnian and Li, Hui},
title = {Pregnane X Receptor Activation Induces Ferroptosis Resistance Through Upregulation of FSP1},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.70016}
}
EUVIMED